title: Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer.
abstract: Hepatocellular carcinoma (HCC) is the second-most common cause of cancer-related death in the world. In spite of HCC surveillance with repeated imaging, about 50% of patients are diagnosed at an advanced stage and are not amenable to curative treatment options. Sorafenib, a multikinase inhibitor, remains the standard of care for advanced HCC. Over the last 5 years, several other medications have been tested in Phase III trials. However, they have not shown any added benefit over sorafenib. Regorafenib, another multikinase inhibitor, has demonstrated inhibition of a broader range of kinases, along with higher inhibition potential in preclinical models. After its safety and pharmacological properties was studied in Phase I trials, a Phase II study evaluating the role of Regorafenib in patients with advanced HCC who progressed on sorafenib therapy demonstrated efficacy and a manageable safety profile. A Phase III trial is ongoing, and its result will help us better evaluate the role of Regorafenib in patients with advanced HCC.
authors.affiliation: Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Sujan
authors.initials: S
authors.lastname: Ravi
authors.affiliation: Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Ashwani K
authors.initials: AK
authors.lastname: Singal
keywords: HCC; Regorafenib; advanced HCC; hepatocellular carcinoma; multikinase inhibitors
references.citation: Hosp Pharm. 2013 Mar;48(3):190-4
references.pmid: 24421459
references.citation: Eur J Cancer. 2011 Sep;47(14):2117-27
references.pmid: 21664811
references.citation: Lancet Oncol. 2009 Aug;10(8):794-800
references.pmid: 19586800
references.citation: Nat Rev Cancer. 2006 Sep;6(9):674-87
references.pmid: 16929323
references.citation: J Clin Oncol. 2013 Oct 1;31(28):3517-24
references.pmid: 23980084
references.citation: Oncogene. 2006 Jun 26;25(27):3787-800
references.pmid: 16799620
references.citation: J Hepatol. 2012 Apr;56(4):908-43
references.pmid: 22424438
references.citation: Hepatology. 2010 Apr;51(4):1274-83
references.pmid: 20112254
references.citation: J Clin Oncol. 2002 Mar 15;20(6):1527-36
references.pmid: 11896101
references.citation: Hepatology. 2011 Mar;53(3):1020-2
references.pmid: 21374666
references.citation: Clin Cancer Res. 2012 May 1;18(9):2658-67
references.pmid: 22421192
references.citation: Dig Dis Sci. 2013 Dec;58(12):3389-96
references.pmid: 24046163
references.citation: J Clin Oncol. 2013 Oct 1;31(28):3509-16
references.pmid: 23980090
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Nat Biotechnol. 2005 Mar;23(3):329-36
references.pmid: 15711537
references.citation: Br J Cancer. 2012 May 22;106(11):1722-7
references.pmid: 22568966
references.citation: Nat Rev Drug Discov. 2006 Oct;5(10):835-44
references.pmid: 17016424
references.citation: J Hepatol. 2012;56 Suppl 1:S75-87
references.pmid: 22300468
references.citation: J Clin Oncol. 2012 Jul 1;30(19):2401-7
references.pmid: 22614970
references.citation: Am J Gastroenterol. 2007 Sep;102(9):1920-30
references.pmid: 17573792
references.citation: Cancer Res. 2008 Aug 15;68(16):6779-88
references.pmid: 18701503
references.citation: Lancet Oncol. 2012 Oct;13(10):1055-62
references.pmid: 22959186
references.citation: J Clin Oncol. 2015 Jan 10;33(2):172-9
references.pmid: 25488963
references.citation: Expert Opin Investig Drugs. 2012 Jun;21(6):879-89
references.pmid: 22577890
references.citation: Int J Cancer. 2011 Jul 1;129(1):245-55
references.pmid: 21170960
references.citation: J Hepatol. 2010 Apr;52(4):550-9
references.pmid: 20206398
references.citation: J Hepatol. 2004 Nov;41(5):864-80
references.pmid: 15519663
references.citation: J Clin Oncol. 2015 Feb 20;33(6):559-66
references.pmid: 25547503
references.citation: J Hepatol. 2008;48 Suppl 1:S20-37
references.pmid: 18304676
references.citation: J Hepatol. 2012 Jun;56(6):1336-42
references.pmid: 22314421
references.citation: Semin Liver Dis. 2007 Feb;27(1):55-76
references.pmid: 17295177
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Br J Cancer. 2001 May 18;84(10):1377-83
references.pmid: 11355950
references.citation: Gastroenterology. 2007 Jun;132(7):2557-76
references.pmid: 17570226
references.citation: J Clin Oncol. 2011 Oct 20;29(30):3960-7
references.pmid: 21911714
references.citation: Semin Liver Dis. 2005;25(2):212-25
references.pmid: 15918149
references.citation: J Clin Oncol. 2013 Nov 10;31(32):4067-75
references.pmid: 24081937
references.citation: J Natl Cancer Inst. 2008 May 21;100(10):698-711
references.pmid: 18477802
references.citation: Eur J Cancer. 2013 Nov;49(16):3412-9
references.pmid: 23809766
references.citation: Cancer. 1985 Aug 15;56(4):918-28
references.pmid: 2990661
references.citation: Oncogene. 2000 Nov 20;19(49):5548-57
references.pmid: 11114734
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206